Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Adacel, Boostrix, Infanrix, Kinrix, Pediarix, Quadracel
Generic Name
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
DrugBank Accession Number
DB10991
Background

Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus that infects the mucosal layers of the human respiratory tract.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Toxoid
Synonyms
  • Bordetella pertussis toxoid vaccine, inactivated
  • Pertussis toxoid

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofPertussis••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AdacelBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg / 0.5 mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (3 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf / 0.5 mL)SuspensionIntramuscularSanofi Pasteur Limited1999-06-23Not applicableCanada flag
ADACEL 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADETBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg/0.5mL) + Bordetella pertussis pertactin antigen (3 mcg/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 Lf/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 Lf/0.5mL)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2017-08-17Not applicableTurkey flag
ADACEL POLIO 0,5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg/0.5mL) + Bordetella pertussis pertactin antigen (3 mcg/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 Lf/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 Lf/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/5mL)Injection, suspensionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2008-12-302022-08-23Turkey flag
Adacel-polioBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg / 0.5 mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (3 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL)SuspensionIntramuscularSanofi Pasteur Limited2011-03-11Not applicableCanada flag
BoostrixBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (2.5 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (20 unit / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 unit / 0.5 mL)SuspensionIntramuscularGlaxosmithkline Inc2007-05-29Not applicableCanada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QSN5XO8ZSU
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911073
RxNav
1300186

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingOtherCoronavirus Disease 2019 (COVID‑19) / Rheumatic Diseases1
4Active Not RecruitingPreventionCervical Carcinoma / Human Papillomavirus (HPV) Infections1
4Active Not RecruitingPreventionPertussis1
4CompletedBasic SciencePrevention of Infections With Bordetella Pertussis1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-acellular Pertussis Vaccines / Tetanus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
SuspensionIntramuscular
Injection
Injection, powder, for suspensionIntramuscular
Injection, suspensionIntramuscular
InjectionIntramuscular
Injection, suspensionIntramuscular; Subcutaneous
Injection, suspension
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:04 / Updated at November 30, 2021 07:50